Febuxostat
Febuxostat is one of 8,063 medications in the MedPlain dataset. Key details — Brand name: Febuxostat; Generic name: FEBUXOSTAT; Drug class: Xanthine Oxidase Inhibitor [EPC].
| Brand name | Febuxostat |
|---|---|
| Generic name | FEBUXOSTAT |
| Drug class | Xanthine Oxidase Inhibitor [EPC] |
| Manufacturer | Hikma Pharmaceuticals USA Inc |
| Used for | 1 INDICATIONS AND USAGE Febuxostat Tablets are a xanthine oxidase (XO) inhibitor indicated for the chronic management of hyperuricemia in adult patients with gout who have an inadequate response to a maximally titrated dose of allopurinol, who are intolerant to allopurinol, or for whom treatment with allopurinol is not advisable. Limitations of Use: Febuxostat Tablets are not recommended for the treatment of asymptomatic hyperuricemia. Febuxostat Tablets are a xanthine oxidase (XO) inhibitor indicated for the chronic management of hyperuricemia in adult patients with gout who have an inadequate response to a maximally titrated dose of allopurinol, who are intolerant to allopurinol, or for wh |
| Dosage | 2 DOSAGE AND ADMINISTRATION • Recommended dosage is 40 mg or 80 mg once daily. The recommended starting dosage is 40 mg once daily. For patients who do not achieve a serum uric acid (sUA) less than 6 mg/dL after 2 weeks, the recommended dosage is 80 mg once daily. ( 2.1 ) • Patients with severe renal impairment: Limit the dosage to 40 mg once daily. ( 2.2 , 8.6 ) • Flare prophylaxis is recommended upon initiation of Febuxostat Tablets. ( 2.4 ) • Can be administered without regard to food or anta |
| Warnings | WARNING: CARDIOVASCULAR DEATH Gout patients with established cardiovascular (CV) disease treated with febuxostat had a higher rate of CV death compared to those treated with allopurinol in a CV outcomes study [see Warnings and Precautions ( 5.1 )] . Consider the risks and benefits of febuxostat when deciding to prescribe or continue patients on febuxostat. Febuxostat should only be used in patients who have an inadequate response to a maximally titrated dose of allopurinol, who are intolerant to |
| Active ingredient(s) | FEBUXOSTAT |
| Route | ORAL |
| Official label | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14f1555c-2565-42c7-b3f5-dd5f03fed67a |